title: Hepatorenal syndrome in cirrhotic patients: terlipressine is a safe and efficient treatment; propranolol and digitalic treatments: precipitating and preventing factors?
authors.forename: C
authors.initials: C
authors.lastname: Duhamel
authors.forename: J
authors.initials: J
authors.lastname: Mauillon
authors.forename: I
authors.initials: I
authors.lastname: Berkelmans
authors.forename: A
authors.initials: A
authors.lastname: Bourienne
authors.forename: J L
authors.initials: JL
authors.lastname: Tranvouez
mesh_terms: D000328:Adult; D000368:Aged; D004074:Digitoxin / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D006530:Hepatorenal Syndrome / Q000139:chemically induced / Q000188:drug therapy*; D006801:Humans; D007677:Kidney Function Tests; D008104:Liver Cirrhosis, Alcoholic / Q000188:drug therapy*; D008236:Lypressin / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D011433:Propranolol / Q000009:adverse effects* / Q000627:therapeutic use; D012008:Recurrence; D000077585:Terlipressin; D014662:Vasoconstrictor Agents / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D014662:Vasoconstrictor Agents; D008236:Lypressin; D000077585:Terlipressin; D011433:Propranolol; D004074:Digitoxin